For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Setmelanotide
Illustration for Setmelanotide

THE PEPSRADAR ENCYCLOPEDIA

Setmelanotide

Rare genetic obesity

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓

Setmelanotide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Imcivree) on DailyMed ↗

What is Setmelanotide?

Setmelanotide is a melanocortin-4 receptor agonist studied in rare genetic forms of obesity. The featured trials enrolled people with POMC or LEPR deficiency, rather than general-population obesity.

Biological role or research focus

Rare genetic obesity.

This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.

Role reference: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Names you may encounter

RM-493

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Melanocortin-4 receptor agonist peptide
Research focus
Rare genetic obesity
Featured evidence
Human open-label phase 3 studies with withdrawal periods
Source check
October 4, 2026

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Quick answers

Is Setmelanotide FDA approved?
Yes. Imcivree (NDA 213793, approved November 2020) for obesity due to POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity (per current label). Source ↗
Is Setmelanotide safe?
Setmelanotide treats rare genetic or hypothalamic obesity; skin darkening, injection-site reactions and nausea are common, and the label warns of depression, sexual side effects and allergic reactions. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Setmelanotide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Setmelanotide in POMC or LEPR deficiency (2020)Human open-label phase 3 studies with withdrawal periods10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human open-label phase 3 studies with withdrawal periods · 2020

Setmelanotide in POMC or LEPR deficiency

What did this publication test, and what did it find?

Population / model
10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older.
Study design
Open-label phase 3 studies with approximately one-year outcomes and blinded withdrawal periods for responders.
Main finding
At least 10% weight loss was reported in 8 of 10 POMC participants and 5 of 11 LEPR participants.
Limits & context
This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

26 registered studies name Setmelanotide as an intervention; 5 are recruiting or under way, 0 have not started recruiting yet, 19 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597 · Rhythm Pharmaceuticals, Inc.
Active, not recruitingPhase 22025-03-0418
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT05093634 · Rhythm Pharmaceuticals, Inc.
CompletedPhase 32022-04-26296
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756 · Rhythm Pharmaceuticals, Inc.
Active, not recruitingPhase 32023-04-26143
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
NCT07496463 · Massachusetts General Hospital
Enrolling by invitationPhase 22026-07-211
Open-Label Extension Study of Setmelanotide
NCT06596135 · Rhythm Pharmaceuticals, Inc.
CompletedPhase 32024-10-2128
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
NCT07674290 · Tom Hühne
RecruitingPhase 42023-01-01200
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546 · Rhythm Pharmaceuticals, Inc.
RecruitingPhase 32025-09-2339
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
NCT04963231 · Rhythm Pharmaceuticals, Inc.
CompletedPhase 22021-11-30164

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 26 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Current Treatments for Patients with Genetic Obesity. ↗
Journal of clinical research in pediatric endocrinology · 2023 May 29 · Review, Journal Article
Read available full text ↗

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. ↗
The lancet. Diabetes & endocrinology · 2022 Dec · Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. ↗
Molecular metabolism · 2017 Oct · Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Pharmacotherapy for Obesity: Recent Updates. ↗
Clinical pharmacology : advances and applications · 2025 · Journal Article, Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Setmelanotide treats rare genetic or hypothalamic obesity; skin darkening, injection-site reactions and nausea are common, and the label warns of depression, sexual side effects and allergic reactions.

Human safety data: FDA label

Safety is established by FDA labeling, based on trials in rare obesity conditions. The label lists no drug interactions and does not recommend use while breastfeeding; long-term data remain limited.

No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

  • Prior serious allergic reaction to setmelanotide or any ingredient

Serious risks

  • Depression and suicidal thoughts
  • Prolonged erections and other sexual side effects
  • Serious allergic reactions, including anaphylaxis
  • Skin darkening, darker existing moles and new moles
  • Sudden adrenal insufficiency in acquired hypothalamic obesity
  • High or low sodium in people with central diabetes insipidus

Common side effects

  • skin darkening
  • injection-site reactions
  • nausea
  • headache
  • diarrhea
  • abdominal pain
  • vomiting
  • spontaneous erections

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Imcivree (setmelanotide) prescribing information ↗

Safety & what remains unknown

Reported effects included injection-site reactions, pigmentation changes, and nausea. The small cohorts cannot exclude uncommon harms.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Evidence boundaries

This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Official product context · checked October 4, 2026

The label includes warnings about depression or suicidal thoughts, sexual-arousal effects, and serious hypersensitivity. Current eligibility and precautions should be read in the complete product label rather than inferred from a receptor mechanism.

Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗

Regulatory status

U.S. FDA approval
Approved
Imcivree (NDA 213793, approved November 2020) for obesity due to POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity (per current label). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Medicine status & clinical context

The March 2026 U.S. Imcivree label includes acquired hypothalamic obesity from age four and specified Bardet-Biedl, POMC, PCSK1, or LEPR-related obesity from age two, with condition-specific diagnostic requirements. General polygenic obesity is outside these labeled indications. The early rare-genetic-obesity trials on this page do not cover every population in the updated label.

The selected trials concern severe early-onset genetic obesity. Current eligibility and medicine precautions require product-specific clinical references.

Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Biology & proposed mechanism

MC4-receptor stimulation was tested in defined upstream genetic signaling disorders. A genetic-disease indication cannot be inferred for everyone with excess weight.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Questions worth asking

  • Do these trials establish effectiveness for common obesity?
  • What material, population, and route were actually studied?
  • This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Do these trials establish effectiveness for common obesity?

No. Their participants had defined rare genetic deficiencies; clinical eligibility depends on the exact condition and current product references.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. · 2020 ↗

Does the official medicine reference cover every use discussed online?

No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.

Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections